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1. Introduction 
Atherosclerosis and its consequences (i.e. myocardial infarction and cardiac death) remain 
the major cause of morbidity and mortality in Western countries (Roger et al. 2011). Despite 
clinical advances that have substantially improved outcomes in patients suffering from 
coronary artery disease, including pharmacological interventions (e.g. novel anti platelet 
therapies, statins, etc.) as well as interventional and surgical therapies (e.g. drug-eluting 
stents), there is still a huge demand for improved diagnostic tools to identify patients at risk 
for adverse events as well as therapeutic means to prevent adverse events in these patients. 
Biomarkers such as high sensitivity CRP (Ridker 2007) or high sensitivity troponin T (Kurz 
et al. 2011) have brought some improvement in identifying patients requiring more intense 
treatment; however, the clinical need for better tools remains. 
An important concept that may help to improve clinical care for patients with coronary 
artery disease is the inducement of plaque stability. Atherosclerotic lesions can show 
features of plaque stability or plaque instability (Naghavi et al. 2003a, Naghavi et al. 2003b). 
Stable plaques are characterized by a thick fibrous cap and a small necrotic core. By contrast, 
unstable plaques display a thin fibrous cap and a large necrotic core consisting of apoptotic 
macrophages, foam cells, and smooth muscle cells. Unstable plaques are more likely to 
rupture, and plaque rupture may subsequently result in thrombosis and occlusion of the 
vessel leading to a myocardial infarction or stroke. 
A promising approach to identify potential markers of plaque instability may be the study 
of atherogenesis on a cellular and molecular level. During the development of 
atherosclerotic lesions, blood monocytes adhere to the activated endothelium, transmigrate 
into the subendothelial space, and differentiate towards macrophages, dendritic cells, or 
foam cells (Galkina & Ley 2009). Among the various leukocyte types involved in 
atherogenesis, monocytes and monocyte-derived macrophages represent the major fraction. 
The monocyte-macrophage differentiation process is affected by the extracellular matrix as 
well as by the combination of chemokines and cytokines representing the micromilieu of the 
plaque (Shashkin et al. 2005). In addition, cell-cell interactions may also affect the fate of 
monocytes within the atherosclerotic plaque. Monocyte-derived cells secrete chemokines, 
cytokines, and other mediators, leading to attraction of other immune cells and thereby 
promoting plaque progression and plaque instability (Shashkin et al. 2005). While it was 
initially thought that monocyte-derived macrophages represent a homogenous population 
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of cells, substantial heterogeneity of human plaque macrophages has been recognized for 
almost two decades (Poston & Hussain 1993). However, only recently has the 
pathophysiological importance of macrophage heterogeneity aroused further scientific 
interest (Bouhlel et al. 2007, Boyle et al. 2009, Gleissner et al. 2010a, Waldo et al. 2008). 
Platelets and platelet-derived mediators represent important players potentially promoting 
macrophage heterogeneity in atherosclerosis. It has been long known that platelets play an 
important role in inflammatory processes reaching far beyond their function in hemostasis 
(Ross 1999). Especially in the context of atherosclerosis, platelets and platelet-derived 
molecules are heavily involved. Thus, platelet-derived chemokines may interact with the 
endothelium as well as with various leukocyte types (Gleissner et al. 2008). Accordingly, 
activated platelets promote atherogenesis as shown in Apoe-/- mice (Huo et al. 2003). This 
effect may in part be chemokine-mediated by promotion of monocyte adherence to the 
endothelium (von Hundelshausen et al. 2001, von Hundelshausen et al. 2005), but it may 
also be a consequence of chemokine-induced monocyte-macrophage differentiation 
(Gleissner et al. 2010a, Gleissner et al. 2010b, Scheuerer et al. 2000). 
The current review will discuss novel insights into the effects of CXCL4, one of the most 
abundant platelet chemokines, on macrophage differentiation in the context of 
atherogenesis. It attempts to summarize what is known about CXCL4-induced 
macrophages, put it into context with knowledge of macrophage heterogeneity in human 
atherosclerosis, and try to answer the question of whether specifically targeting these 
CXCL4-induced macrophages may be a promising approach to prevent or treat 
atherosclerosis in humans. 
2. Macrophages and atherogenesis 
2.1 Studying macrophages in human and murine models 
Studying myeloid cells and especially monocyte-derived macrophages in humans is a 
difficult task. While monocytes can easily be isolated from human peripheral blood and 
differentiated towards macrophages in order to perform in vitro studies, the possibility of 
studying human macrophages within atherosclerotic lesions is restricted to the analysis of 
post mortem tissues or explanted tissues, e.g. of carotid endatherectomy specimens or 
explanted hearts after heart allograft transplantation. Even though these materials will allow 
studying macrophages within their pathophysiological environments, the systems may still 
be biased by post mortem processes or effects due to prolonged ischemic time resulting in 
changes that do not allow correctly assessing the in vivo situation. 
On the other hand, using mouse models to study monocytes and monocyte-derived 
macrophages offers great potential by using differently-labeled or genetically modified 
monocyte subsets (e.g. using the CXC3CR1 FITC mice) that allow the generation impressive 
in vivo tracking models that have helped to identify differential roles of specific monocyte 
subsets (Auffray et al. 2007, Geissmann et al. 2003). However, these systems have one 
notable problem: it is extremely difficult to transfer the information gained from these 
mouse models to the human system. Thus, some of the markers used to identify murine 
monocyte subsets (e.g. Gr-1. Ly6C, etc.) do not exist in the human system or do not have a 
human marker that clearly corresponds to them. Furthermore, in many aspects, murine 
monocyte-derived macrophages behave differently from human macrophages. Thus, 
treating murine macrophages with lipopolysaccharide (LPS) leads to increased uptake of 
modified LDL (Fitzgerald et al. 2000). Conversely, treating human macrophages with LPS 
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prevents uptake of modified LDL (own unpublished observation). Considering that uptake 
of modified LDL represents a crucial step during macrophage foam cell formation with 
great impact on atherogenesis, it becomes questionable as to how relevant results from 
murine experiments may be for the human situation.  
A recent extremely valuable study has compared the transcriptomes of human and murine 
monocyte subsets (Ingersoll et al. 2010). In this study, the authors used CCR2 and CXC3CR1 
to identify the two murine monocyte subsets, whereas CD14 and CD16 were used to 
differentiate between the human monocyte subsets. About 270 genes in humans and 550 
genes in mice were differentially-expressed between the monocyte subsets. Interestingly, 
only about 130 were conserved between species and a substantial number of genes were 
found to be differentially-expressed in a cross-species comparison. Among those, the 
authors identified genes extremely important in atherogenesis, including the scavenger 
receptors CD36 or macrophage scavenger receptor-A, as well as other functionally 
important molecules such as receptors for apoptotic cells. Again, this supports the notion 
that there are considerable differences between the human and murine system, and that 
results from murine experiments should be taken with care when drawing conclusions for 
human atherosclerosis. 
Based on these considerations, the current article will specifically focus on data derived 
from studies on human macrophages wherever possible. Murine data will only be referred 
to when no data on human cells are available. 
2.2 Macrophage heterogeneity 
2.2.1 General concept of macrophage plasticity and polarization 
A central feature of macrophages is their plasticity. Macrophage plasticity is defined as the 
capacity of the cell to readily change its phenotypic and functional capacities depending on 
the external conditions. Thus, the repertoire of surface receptors, the ability to generate 
reactive oxygen species, and the potential to migrate towards specific chemoattractants can 
differ substantially depending on the external conditions. By contrast, the term macrophage 
polarization is used for defined states of macrophage plasticity, which can be induced by 
specific conditions (e.g. combination of cytokines) and is defined by the presence of specific 
surface markers or functional capacities.  
In vivo, the conditions inducing or preventing macrophage plasticity and polarization are 
probably determined primarily by the micromilieu. In fact, the presence of differentially-
polarized macrophages has been postulated early on (Poston & Hussain 1993) and has been 
confirmed within human atherosclerotic lesions by various groups including ourselves 
(Bouhlel et al. 2007, Boyle et al. 2009, Gleissner et al. 2010a, Waldo et al. 2008). These 
findings make clear that macrophages within one atherosclerotic plaque can not be 
considered to be a uniform cell population but may have different functions depending on 
their specific polarization type. 
2.2.2 Accepted models of macrophage polarization 
There is currently a well defined scheme of macrophage polarization in vitro and in vivo. The 
first to describe an “alternative” macrophage activation were Gordon et al., who demonstrated 
that upon stimulation with IL-4, macrophages express high levels of mannose receptor CD206 
(Stein et al. 1992). Based on this finding, the paradigm of “classically” activated M1 
macrophages and “alternatively” activated M2 macrophages became accepted (Fig.1).  
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Fig. 1. The established paradigm of macrophage polarization. While M1 macrophages are 
thought to be involved in type I inflammation (bacterial killing or tumor resistance), M2 
macrophages are associated with type II inflammation (allergy, parasital killing).  For each 
polarization type, typical cytokines, chemokines, chemokine receptors, other receptors, 
surface molecules involved in antigen presentation, and intracellular enzymes are indicated. 
According to this paradigm, M1 macrophages can be induced by a combination of 
interferon- and LPS or by tumor necrosis factor- and are characterized by expression of 
pro-inflammatory cytokines like interleukin-1, interleukin-6, tumor necrosis factor-, or 
interferon-. Furthermore, M1 macrophages express chemokines like CLL2 or CCL5, surface 
receptors like TLR2 or TLR4, and enzymes like iNOS. It is thought that M1 macrophage 
polarization mirrors the Th1 response of T cells, i.e. they represent a rather pro-
inflammatory type of macrophage.  
By contrast, M2 macrophages can be induced by Th2 cytokines like IL-4. They can express Th2 
cytokines like IL-10 and are specifically characterized by the expression of surface receptors 
like CD163, CD206 (mannose receptor), or scavenger receptor-A and CD36. Since the first 
description of alternative macrophage activation has been published, several additional types 
of M2 macrophages have been identified, now defined as M2a (induced by IL-4 or Il-13), M2b 
(induced by immune complexes and TLR ligands), and M2c (induced by Il-10). Overall, M2 
macrophages reflect the Th2 response and can be considered rather anti-inflammatory. 
M1 and M2 macrophage polarization have been extensively studied including a 
comprehensive transcriptomic analysis of both macrophage polarization types (Martinez et 
al. 2006). In this gene array analysis, Martinez et al. confirmed the basic M1-M2 paradigm. 
Interestingly, monocyte-macrophage differentiation induced by MCSF alone leads to 
expression of many M2 genes, suggesting that basal conditions favour a default shift toward 
M2. Beyond this novel finding, the authors identified specific gene clusters involved in lipid 
metabolism, specific clusters of G protein-coupled receptors, and specific chemokines 
clusters in both M1 and M2 macrophages (Martinez et al. 2006). Both M1 and M2 
macrophage polarization have been excellently reviewed by Gordon et al. as well as by 
Mantovani (Gordon 2003, Mantovani et al. 2009). 
www.intechopen.com
 CXCL4-Induced Macrophages: A Novel Therapeutic Target in Human Atherosclerosis? 
 
349 
3. Platelet factor-4 (CXCL4), macrophages, and atherogenesis 
3.1 CXCL4 – A platelet-derived chemokine in atherogenesis 
Platelets and platelet-derived chemokines are important factors during atherogenesis 
(Gleissner et al. 2008, von Hundelshausen et al. 2007, Weber 2005, Weber 2008, Zernecke et 
al. 2008). In 2003, Ley et al. were able to demonstrate that activated platelets are able to 
promote atherogenesis (Huo et al. 2003). Upon activation, platelets release various 
chemokines from their alpha granules. Furthermore, activated platelets present or deposit 
chemokines and thereby induce recruitment of other cells to the arterial wall.  
Among the plethora of chemokines released from activated platelets, CXCL4 (formerly 
known as platelet factor-4) is one of the most abundant. Accordingly, CXCL4 is released in 
human blood in micromolar concentrations upon platelet activation (Brandt et al. 2000). 
CXCL4 has been considered an “enigmatic” chemokine as it lacks the ELR domain typically 
seen in CXCL chemokines (Gear & Camerini 2003) and has been demonstrated to have 
effects on various cell types including endothelial cells, lymphocytes, neutrophils, and 
monocytes (Gleissner et al. 2008). However, the mechanisms by which CXCL4 exerts its 
effects, including receptors and signal transduction, have not fully been elucidated. Notably, 
CXCL4 has been demonstrated to induce monocyte adhesion to endothelial cells in 
conjunction with CCL5 (RANTES) (von Hundelshausen et al. 2005) and to promote 
macrophage differentiation from human peripheral blood monocytes (Scheuerer et al. 2000). 
Both mechanisms may be relevant during atherogenesis. 
3.2 CXCL4 and macrophage differentiation 
A role for CXCL4 for monoycte-macrophage differentiation has been suggested by Scheuerer 
et al. in 2000 (Scheuerer et al. 2000). Their data demonstrate that CXCL4 not only acts in an 
anti-apoptotic manner on human peripheral blood monocytes, but also promotes their 
differentiation towards macrophages in a dose-dependent manner as demonstrated by 
increased myeloperoxidase expression. The fact that these CXCL4-induced macrophages do 
not express any detectable CD86 levels on their cell surface suggested that they may be 
different from those induced by the typically used growth factor macrophage colony-
stimulation factor MCSF (Scheuerer et al. 2000).  
Interestingly, these first data had been abandoned for almost a decade. One reason for this 
may be the fact that up to now, nobody has been able to identify the CXCL4 receptor on 
human monocytes and macrophages. While on T cells and microvascular endothelial cells 
CXCR3 or splice variants thereof like CXCR3B (Lasagni et al. 2003) have been clearly 
identified, it is still not clear by which receptor and signal transduction CXCL4 acts on 
human myeloid cells. Accordingly, it was not until 2010 that our own group did a 
comprehensive gene expression screen on these cells revealing novel insights into the 
potential role of CXCL4-induced macrophages (Gleissner et al. 2010b). 
3.3 Potential role of CXCL4-induced macrophages in human atherosclerosis 
3.3.1 General considerations 
Monocyte-derived macrophages are present in atherosclerotic lesions at very early stages of 
the disease (Galkina & Ley 2009). Activated platelets have been demonstrated to promote 
atherogenesis, an effect mediated by chemokines released from their alpha granules (Huo et 
al. 2003). CXCL4 is one of these platelet chemokines and is released from platelets upon 
activation (Brandt et al. 2000). CXCL4 is known to prevent monocyte apoptosis (Scheuerer et 
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al. 2000) and to promote differentiation of a specific macrophage phenotype distinct from 
previously identified macrophage polarizations (Gleissner et al. 2010b). Taking into account 
that the genetic deletion of CXCL4 in Apoe-/- mice is accompanied by reduced atherogenesis 
(Sachais et al. 2007), and that in human atherosclerotic lesions the presence of CXCL4 has 
been associated with plaque progression and clinical symptoms (Pitsilos et al. 2003), it seems 
extremely reasonable to hypothesize that CXCL4-induced macrophages significantly 
contribute to atherogenesis and progression of atherosclerosis. An important mechanisms of 
this action may represent the induction of CXCL4-specific, pro-atherogenic macrophages. 
3.3.2 Features of CXCL4-induced macrophages – The M4 macrophage 
To identify potential mechanisms by which CXCL4-induced macrophages are induced to act 
in a pro-atherogenic manner, we studied their transcriptome and compared it to that of 
MCSF-induced macrophages from the same donors. In this analysis, we found that both 
MCSF- and CXCL4-induced macrophages have strong phenotypic similarities. Thus, they 
both express similar mRNA and surface levels of CD45, CD14 or intracellular levels of 
CD68. Their transcriptomes show a strong correlation clearly indicating that they both 
represent macrophages  (Gleissner et al. 2010b). 
Interestingly, while CXCL4-treated human monocytes display phenotypic and functional 
characteristics of macrophages after six days in culture, they also have characteristics that 
clearly distinguish them from MCSF-induced macrophages. We found 375 genes 
differentially-expressed between MCSF- and CXCL4-induced macrophages, 206 of them being 
over-expressed in CXCL4-induced macrophages. Interestingly, CXCL4-induced  macrophages 
displayed neither typical markers of M1 nor of M2 polarization (Gleissner et al. 2010b). 
Accordingly, using different statistical approaches including gene set enrichment analyses 
(Subramanian et al. 2005), modified principal components analysis (PCA), and hierarchical 
clustering (based on transcriptomic data from MCSF-treated, M1-polarized and M2-polarized 
macrophages (Martinez et al. 2006)), we were able to demonstrate that CXCL4 induces a 
transcriptome distinct from every macrophage polarization type described thus far (Gleissner 
et al. 2010b). In all statistical models, it turned out that in relation to their corresponding 
MCSF-control macrophages, M1 (induced by LPS and interferon-γ) and M2 macrophages 
(induced by IL-4) clustered together more closely than CXCL4-induced macrophages.  
These findings suggest that CXCL4 induces a macrophage phenotype with specific 
phenotypic and functional characteristics, which will be discussed in more detail below. 
Based on these results, we have suggested calling these macrophages M4 – a term that we 
believe reflects both the fact that these cells are distinct from M1 and M2 macrophages and 
that they can be induced by CXCL4. Accordingly, in the following paragraphs CXCL4-
induced macrophages will be referred to as M4 macrophages. Fig. 2 summarizes some of the 
findings described below in more detail. 
3.3.3 Gene expression of matrix metalloproteinases in M4 macrophages 
Considering that CXCL4 promotes atherogenesis in Apoe-/- mice, we hypothesized that M4 
macrophages would over-express genes that are involved in atherogenesis as compared to 
their MCSF-induced counterparts. Therefore, it was a surprise to discover that M4 
macrophages cannot generally be considered pro-atherogenic: some genes implicated in 
atherogenesis showed higher expression levels, others lower expression levels as compared 
to MCSF-induced macrophages.  
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Fig. 2. Features of MCSF- and CXCL4-induced macrophage (M0 and M4 macrophages). For 
each polarization type, typical cytokines, chemokines, chemokine receptors, other receptors, 
surface molecules involved in antigen presentation, and intracellular enzymes are indicated. 
The figures at the bottom indicate functional differences regarding scavenger receptor 
expression, uptake of modified LDL and the differential potential to clear hemoglobin-
haptoglobin complexes resulting in heme oxygenase-1 upregulation. 
This ambiguous picture was also seen with matrix metalloproteinases (MMP), of which 
some showed higher expression in M4 macrophages (e.g. MMP7 or MMP12) while others 
were expressed more highly in MCSF-induced macrophages (e.g. MMP8). Of course, gene 
expression data do not necessarily reflect protein expression and in the case of MMPs, 
enzyme activities may be also differentially-regulated; the regulation of MMPs is 
furthermore affected by activation through cathepsins, which in part are also differentially-
regulated (cathepsin B and K significantly higher in M4 macrophages) (Newby 2008).  
Taken together, due to the lack of functional data at this stage, it is impossible to judge 
whether differential-expression of MMPs and potentially different MMP activity in M4 
macrophages represent a pro-atherogenic feature of M4 macrophages. 
3.3.4 Foam cell formation in M4 macrophages 
Based on previous data, that CXCL4 promotes atherogenesis in Apoe-/- mice, we 
hypothesized that CXCL4-induced macrophages would be more prone to foam cell 
formation induced by modified (i.e. acetylated or oxidized) low density lipoprotein (LDL). 
Interestingly, the opposite was the shown to be true. While cholesterol efflux transporter 
ABCA1 and ABCG1 were not differentially-expressed on the mRNA level, scavenger 
receptors involved in uptake of modified LDL showed significantly lower expression in 
CXCL4-induced macrophages. Specifically, CD36 and macrophage scavenger receptor-A 
(which both account for the vast majority of uptake of modified LDL during macrophage 
foam cell formation) showed significantly lower mRNA expression, while the differences 
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measured by flow cytometry were only significant for CD36. Interestingly, both uptake of 
acetylated and oxidized LDL (acLDL and oxLDL) was significantly lower in M4 
macrophages, suggesting that CXCL4-induced macrophages have a lower tendency to 
differentiate towards foam cells. This was somewhat unexpected and supports the notion 
that the pro-atherosclerotic effects of CXCL4 as shown in Apoe-/- likely reflects a multitude of 
different effects, including those on cells other than macrophages (i.e. endothelial cells, T 
cells, and potentially smooth muscle cells). 
3.3.5 CD163 and heme oxygenase-1 in M4 macrophages 
When analyzing the transcriptome of M4 macrophages, we found CD163 mRNA coding for 
the hemoglobin-haptoglobin scavenger receptor to be significantly down-regulated as 
compared to MCSF-induced macrophages (Gleissner et al. 2010a). CD163 binds hemoglobin-
haptoglobin complexes (and hemoglobin with lower affinity). Binding of the ligand to 
CD163 results in upregulation of heme oxygenase-1 (Schaer et al. 2006). Heme oxygenase-1 
(and specifically heme oxygenase-1 expressed in bone marrow-derived cells like monocytes 
and monocyte-derived macrophages) is thought to be atheroprotective as demonstrated in 
several mouse models (Juan et al. 2001, Orozco et al. 2007, Yet et al. 2003). 
Further experiments studying gene and protein expression in freshly isolated blood 
monocytes and macrophage induced either by MCSF or CXCL4 confirmed the significant 
differences. Thus, while MCSF treatment resulted in further up-regulation of CD163 
expression, exposure to CXCL4 resulted in complete loss of the receptor within hours. This 
loss was not mediated by shedding of the receptor, which is one mechanism by which 
CD163 surface expression can be down-regulated (e.g. after treatment with LPS (Buechler et 
al. 2000)). Functionally, loss of CD163 resulted in loss of heme oxygenase-1 up-regulation 
upon exposure to hemoglobin-haptoglobin complexes confirming the functional relevance 
of our findings. 
To assess whether these in vitro findings play a role in vivo, we studied CD163 protein 
expression in human atherosclerotic lesions and found that it is differentially-expressed on 
CD68+ macrophages (Gleissner et al. 2010a). Furthermore, in a cohort of 18 consecutive 
patients undergoing carotid endatherectomy we found an inverse correlation between gene 
expression of PF4 (coding for CXCL4) and CD163. Considering that PF4 is exclusively 
expressed in megakaryocytes and platelets and CD163 expression is restricted to myeloid 
cells, we concluded that the presence of large amounts of CXCL4 is associated with low 
levels of CD163 supporting that this mechanism does play a role in vivo. 
3.4 M4 macrophages as therapeutic target in atherosclerosis? 
As described above, macrophages present in human atherosclerotic lesions do not represent 
a homogeneous entity, but are composed of different subsets that are characterized by 
differential-expression of cytokines, chemokines, surface receptors and their enzymatic 
repertoire. We believe that the platelet-derived chemokine CXCL4 may represent an 
important inducer of macrophage heterogeneity as it (I) is present in the atherosclerotic 
lesions, (II) is associated with disease progression, and (III) promotes monocyte 
differentiation towards a distinct macrophage polarization type.   
Based on these considerations, it was surprising to discover that CXCL4-induced M4 
macrophages do not display a clearly pro-atherogenic phenotype. In fact, some of their 
features seem clearly pro-atherogenic (e.g. loss of CD163), while others are ambiguous (e.g. 
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MMP expression) or may even be anti-atherogenic (e.g. reduced uptake of modified LDL). 
However, many of these functional data have been obtained in vitro on isolated 
macrophages. Thus, it is possible that in the context of an atherosclerotic lesion consisting of 
extracellular matrix as well as various other cells types, CXCL4-induced macrophages may 
have a more clearly pro-atherogenic phenotype. On the other hand, it is possible that the 
pro-atherogenic effects of CXCL4 represent the summary of various effects on various cell 
types. 
The possibility to specifically address the interaction between a chemokines and its partner 
(in this case CXCL4 and CCL5 (RANTES)) in the context of atherogenesis has been 
demonstrated in a very elegant study by Koenen et al., who have designed a small molecule 
that specifically inhibits the interaction between those two chemokines (Koenen et al. 2009). 
When treating Apoe-/- mice with this substance, lesion development was significantly 
reduced. Even though at this point it is unclear to what extent this effect was due to direct 
inhibition of CXCL4 effects on macrophages, it still demonstrates that tackling pro-
atherogenic chemokines represents a promising approach to prevent or even treat 
atherosclerosis. 
4. Macrophage heterogeneity and the novel M4 macrophage 
4.1 Unresolved questions on macrophage heterogeneity 
There are a number of unresolved questions regarding macrophage heterogeneity, which 
make it difficult to assess the specific role of M4 macrophages in this context. Firstly, in 
vitro models usually do not account for the diversity of peripheral blood monocytes. 
Thus, CD14+ cells are used to generate macrophages and it is unknown whether certain 
monocyte subsets (Geissmann et al. 2010, Ziegler-Heitbrock 1989) may be more likely to 
differentiate towards a specifically polarized macrophage type than others. Secondly, the 
concept of macrophage polarization is somewhat artificial as it considers the effects of 
isolated soluble factors (like TNF-alpha or IL-4), whereas in vivo the local micromilieu 
may be composed of a combination of various cytokine and chemokines. Thirdly, when 
studying macrophage polarization in vitro, dynamics over time are rarely being taken into 
account. Even though Mantovani et al. have studied the transcriptomes of monocytes, and 
monocyte-derived macrophages after three or six days’ treatment with MCSF (plus 
additional treatment with LPS/interferon- (M1) or IL-4 (M2)) (Martinez et al. 2006), more 
detailed information on time courses are lacking at this point. Finally, we do not know 
exactly which of the thus far defined macrophage polarization types represent final states 
of differentiation and which of them are temporary, i.e. whether induction of a specific 
polarization type is reversible or not.  
4.2 Macrophage polarization beyond M1 and M2 
The recent data on macrophage heterogeneity in human atherosclerosis is interesting and 
puzzling at the same time. Thus, while Bouhlel et al. were able to demonstrate gene 
expression of both M1 and M2 markers in different areas of human atherosclerotic plaques 
suggesting that both polarization types may exist in vivo (Bouhlel et al. 2007), other groups 
including ourselves have described macrophage phenotypes in vitro and in vivo that do not 
necessarily fit into the established scheme of macrophage polarizations (Boyle et al. 2009, 
Gleissner et al. 2010a, Waldo et al. 2008).  
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Waldo et al. compared MCSF- and GMCSF-induced macrophages (even though the latter 
are sometimes considered dendritic cells) and found significant differences in the expression 
of CD14, which was virtually absent in GMCSF-induced cells (Waldo et al. 2008). 
Furthermore, these cells were less likely to spontaneously accumulate modified LDL. The 
authors were able to confirm the existence and the functional characteristics of these 
macrophages in vitro as well as in human atherosclerotic lesions. 
Boyle et al. described a novel macrophage that is induced by haemoglobin-haptoglobin 
(Hb-Hp) complexes and is characterized by high levels of CD163 and low levels of HLA-
DR (Boyle et al. 2009). In vitro, these cells cleared Hb-Hp complexes more efficiently and 
showed reduced oxidative stress (Boyle et al. 2009). Mechanistic data show, that this 
phenotype is induced by autocrine effects of IL-10 suggesting a certain similarity to M2c 
macrophages.  
Our own group has studied the effects of oxidized LDL on human monocyte-derived 
macrophages and found that these cells express markers that have been associated with 
dendritic cells (Cho et al. 2007). Thus, these cells up-regulate genes coding for MHC-II, 
CD11c, and DC-STAMP, suggesting that there may be phenotypic and functional overlap 
between foam cells and dendritic cells within atherosclerotic lesions. 
Finally, as mentioned above, we have studied the phenotypic and functional characteristics 
of CXCL4-induced macrophages and found features that clearly distinguish these 
macrophages from any polarization type described thus far (Gleissner et al. 2010b).  
4.3 Suggestion for a novel nomenclature of macrophage polarization 
Based on this evidence, we feel the necessity to develop a novel classification of macrophage 
polarization that includes the novel macrophage types described in vitro and in vivo over the 
past years. Therefore, we here propose a novel framework that tries to systematically cover 
those macrophage types that have been unequivocally identified in human atherosclerotic 
plaques. Many of these polarization types have been extensively characterized, sometimes 
including transcriptomic analysis. Accordingly, we suggest assigning the “novel” 
macrophage polarization types names that consist of “M” (for macrophage) and a second 
number, or letter, or combination of both that is related to the inducers of this polarization 
type.  
Our proposed system has several advantages: Firstly, it allows keeping the established 
terms M1 and M2 and thereby not only respects the pioneering work by Gordon et al., but 
also avoids confusion associated with the introduction of new terms. Secondly, for 
“novel” macrophage polarization types the proposed names hint as to what inducers are 
involved. Finally, the system allows flexibility as based on the above-mentioned 
principles, so further addition of novel macrophage polarization types remains possible in 
the future.  
Notably, the proposed nomenclature is restricted to monocyte-derived cells that occur 
during pathology, i.e. it does not cover tissue macrophages like Kupffer cells in the liver or 
alveolar macrophages in the lung. By including dendritic cells (DC) in the system, we 
specifically address myeloid dendritic cells derived from monocyte precursors. 
Plasmacytoid DCs or DCs constitutively present in certain tissues like Langerhans cells of 
the skin are again not covered by the proposed system. Accordingly, our system may have 
some overlap with other classifications of DCs. Table 1a and b give an overview of the 
proposed system. 
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 M1 M0 M2a M2b M2c 
Inducers 
MCSF 
+ IFN/ LPS 
or 
TNF-α 
MCSF 
IL-4 
or 
IL-13 
Immune 
complexes + 
TLR ligands 
IL-10 
Prominent 
markers 
(selection) 
CCR7, TLR2, 
TLR4, MHC-II, 
iNOS 
CD14, CD16, 
CD163 
CD36, CD163, 
MR, SR-A, 
MHC-II 
CD80, CD86, 
MHC-II 
CCR2, CD14, 
CD36, MR, SR-
A 
Functional 
characteristics 
Pro-
inflammatory 
Inflammation 
resolution? 
Inflammation 
resolution 
Inflammation 
resolution 
Tissue repair 
Transcriptome  Yes yes yes no no 
In vivo evidence 
in athero-
sclerosis 
Gene 
expression 
Gene 
expression 
Gene 
expression 
no no 
References for 
transcriptomic 
analysis 
(Martinez et 
al. 2006) 
(Cho et al. 
2007, Gleissner 
et al. 2010b, 
Martinez et al. 
2006, Waldo et 
al. 2008) 
(Martinez et 
al. 2006) 
- - 
Table 1a. Proposal for a novel macrophage classification (established polarization types). 
The columns are ordered in a way that reflects similarity based on transcriptomic analysis 
where available.  
 
 M-Hb M4 M-ox M-GM M-DC 
Inducers 
MCSF + 
hemoglobin/
haptoglobin 
CXCL4 
MCSF + 
oxLDL 
GMCSF GMCSF + IL-4 
Prominent 
markers 
(selection) 
CD163 
 
MHC-IIlow 
 
 
CD163- 
CD206,  
MHC-II 
CD1a, CD1c, 
CCR7 
CD14- 
CD206,  
MHC-II 
Functional 
characteristics 
High 
clearance of 
Hb/hp, 
reduced 
oxidative 
stress 
Defective 
Hb/hp 
clearance, 
reduced foam 
cell formation 
Ag 
presentation? 
Less 
spontaneous 
cholesterol 
accumulation,
unclear 
Ag 
presentation, 
T cell 
activation 
Transcriptome No Yes Yes Yes Yes 
In vivo evidence 
in athero-
sclerosis 
Histology 
Gene 
expression, 
histology 
(CD163) 
Histology 
Histology 
(CD68) 
Histology 
References 
(Boyle et al. 
2009) 
(Gleissner et 
al. 2010b) 
(Cho et al. 
2007) 
(Waldo et al. 
2008) 
(Bobryshev & 
Lord 1995, 
Jeffrey et al. 
2006) 
Table 1b. Proposal for a novel macrophage classification (novel polarization types). The 
columns are ordered in a way that reflects similarity based on transcriptomic analysis where 
available 
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5. Conclusions 
In summary, we have discussed the role of the platelet-derived chemokine CXCL4 for 
macrophage differentiation in the general context of macrophage heterogeneity in 
atherogenesis. There is good evidence that CXCL4 promotes atherogenesis, even though at 
this point, the relevance of CXCL4-induced macrophages for this process is not entirely 
understood. While CXCL4-induced macrophages display some potentially pro-atherogenic 
features, their pro-atherogenic nature is not as evident as expected. Thus, we believe that it 
will be necessary to study these cells in more detail to elucidate the mechanisms involved in 
CXCL4-induced macrophage differentiation, but also to study these cells in their 
pathohpysiological environment, i.e. within the human atheroclerotic plaque.  
As CXCL4 is not the only mediator of monocyte macrophage differentiation and as an 
increasing number of polarized macrophages clearly distinct from M1 and M2 macrophages 
with potential implication for atherogenesis have been identified in vitro and in vivo, we 
have proposed a novel macrophage classification schema, that both respects the established 
M1 and M2 paradigm and takes into account novel macrophage phenotypes and their 
inducers.  
Taken together, even though our knowledge on macrophage heterogeneity in general and 
the impact of CXCL4 on macrophage heterogeneity in atherogenesis is growing, we still 
need more insight into the mechanisms involved  in order to use this knowledge as the basis 
for novel, specific therapies for atherosclerosis. 
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